Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 28.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 325,996 shares of the biotechnology company’s stock after buying an additional 71,387 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Grifols were worth $2,178,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in GRFS. China Universal Asset Management Co. Ltd. increased its position in shares of Grifols by 350.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,111 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 10,979 shares during the last quarter. Morningstar Investment Services LLC purchased a new position in shares of Grifols in the 4th quarter valued at $186,000. International Assets Investment Management LLC purchased a new position in shares of Grifols in the 4th quarter valued at $398,000. QRG Capital Management Inc. grew its position in shares of Grifols by 5.9% in the 4th quarter. QRG Capital Management Inc. now owns 35,116 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 1,964 shares during the last quarter. Finally, Team Hewins LLC purchased a new position in shares of Grifols in the 4th quarter valued at $422,000.

Grifols Price Performance

Grifols stock remained flat at $6.31 during trading on Friday. 1,319,401 shares of the company were exchanged, compared to its average volume of 916,999. Grifols, S.A. has a 52-week low of $5.30 and a 52-week high of $12.15. The business’s 50-day moving average price is $7.01 and its 200 day moving average price is $7.70. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.29 and a current ratio of 2.79.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft cut shares of Grifols from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.